In animals submitted to the therapy with MK0431 (group II) it was

In animals submitted to the therapy with MK0431 (group II) it was observed involuted serous acini. However, a recovery was noted when compared to untreated animals (Fig. 1A and Table 3 and Table 4). Stromal spaces filled with extracellular matrix were identified between acini by Picrosirius red staining. The quantity of collagen fibres was significantly Y-27632 order minor than that

observed in untreated animals (Fig. 1C and Table 5). Pleomorphic serous acini characterized by a reduced spatial area occupied by secretory epithelium were observed in parotid glands of the group I (Fig. 1B and Table 3 and Table 4). The stroma was found enlarged, with a higher volume density of collagen fibres (Fig. 1D and Table 5). Similarly, animals submitted to therapy with MK0431 (group II) presented also involuted seromucous acini; however, learn more a significant recovery was also noted when compared to untreated animals (Fig. 2A and Table 3 and Table 4). In the same way, stromal spaces filled with extracellular matrix were identified between acini by Picrosirius red staining. The quantity of collagen fibres was significantly minor (Fig. 2C and Table 5).

In submandibular glands, atypical and involuted seromucous acini were observed in the group I (Fig. 2B and Table 3 and Table 4). Enlargement of the interacinar spaces were also observed. Extracellular matrix alterations were observed Astemizole in the stroma, with the observation of increase in the connective tissue component (Fig. 2D and Table 5). Diabetic animals presented the lowest weight throughout the experimental period. Diabetes mellitus causes metabolic disorders and body weight alteration.29, 30, 31 and 32 Animals submitted to glycaemic treatment, showed recovery of body weight.33

Body weight recovery and gain were observed also after use of incretin-based therapies; however, this cannot reflect an adequate metabolic control. An alternative to the diabetes treatment and weight control is the use of DDPIV inhibitors, as the sitagliptin (MK0431). This incretin mimetic promotes the maintenance and in different cases the loss of weight, as observed in both type 1 and 2 diabetes.14, 17, 18, 34, 35 and 36 Therefore, while weight gain can exacerbate hyperglycemia, the minor weight observed in treated animals may be related to the beneficial effect of treatment with this DPPIV inhibitor. As per to glucose levels, it was observed elevated levels throughout the experimental period in animals of group I, and a significant reduction of glucose levels was observed in animals of group II. In a study using insulin replacement therapy, a proven hypoglycaemic treatment, Hu et al. 37 showed that normal glucose levels in healthy animals are close to 180 mg/dL, whereas mean levels of 300 mg/dL or higher indicate an effective diabetic state.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>